A short, 60 seconds read that summarises 4 handpicked articles that are worth reading about:
OUR LATEST ARTICLE: What are the new Integrated Care Systems replacing Clinical Commissioning Groups in England and what is the impact of the delay to their implementation?
NICE recommends CDF use of dostarlimab
Global Blood Therapeutics’ treatment for patients with sickle cell disease approved in Europe
Institute of Cancer Research labels NICE reforms a missed opportunity
We examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...
Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.